ANTI-MERTK CLONE 2E14 ZOOMAB RABBIT MONOCLONAL (C15-1670-001)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 2E14 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Tyrosine-protein kinase Mer (MerTK). It targets an epitope within 19 amino acids from the C-terminal, cytoplasmic domain.

Immunogen

KLH-conjugated linear peptide corresponding to 19 amino acids from the C-terminal, cytoplasmic domain of human Tyrosine-protein kinase Mer (MerTK).

Application

Quality Control Testing

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected MerTK in HepG2 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected MerTK in lysates from HEK293 cells and Rat testis tissue.

Affinity Binding Assay: A representative lot of this antibody bound MerTK peptide with a KD of 7.9 x 10-7 in an affinity binding assay.

Immunohistochemistry Applications: A representative lot detected MerTK in human adrenal gland tissue sections.

Flow Cytometry Analysis: 0.1 μg from a representative lot detected MerTK in one million U937 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

Tyrosine-protein kinase Mer (UniProt: Q12866; also known as EC:2.7.10.1, Proto-oncogene c-Mer, Receptor tyrosine kinase MerTK) is encoded by the MERTK (also known as MER) gene (Gene ID: 10461) in human. MerTK is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-20), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 21-505), a transmembrane domain (aa 506-526), and a cytoplasmic domain (aa 27-999). Its protein kinase domain is localized to amino acids 587-858. MerTK is highly expressed in testis, ovary, prostate, lung, and kidney tissue. Its expression is not observed in normal B- and T-cells but is expressed in several neoplastic B- and T-cell lines. Overexpression of MerTK has also been reported in non-small cell lung cancer (NSCLC). It is involved in the regulation of cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands, including galectin-3, Tubby protein, Tubby-related protein 1, and GAS6, a member of the Axl subfamily of receptor protein-tyrosine kinases. Ligand binding at the cell surface induces autophosphorylation of MerTK on its intracellular domain that provides docking sites for downstream signaling molecules. Its autophosphorylation on tyrosine 749, 753, and 754 in the activation loop imparts full activity. It is also autophosphorylated on tyrosine 872 that leads to recruitment of downstream partners of the signaling cascade such as phospholipase C 2. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Cummings, CT., et al. (2014). Oncotarget, 5(21); 10434-45; Rogers, AEJ., et al. (2012). Oncogene. 31(38): 4171 4181).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.